Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation.

"Disclosure Lalit Saini received consulting fees and honoraria for participation on an advisory board from Astellas. James D. Griffin received consulting fees from Astellas and reports grants from Novartis Pharma, outside the submitted work. Bhavik J. Pandya is an employee of Astellas. Manasee V. Shah is a former employee of Astellas. Mo Zhou received consulting fees paid to Analysis Group from Astellas. Hongbo Yang received consulting fees paid to Analysis Group from Astellas. Yan Song received consulting fees paid to Analysis Group from Astellas. Deborah A. Marshall received consulting fees from Astellas. She also reports travel expenses and honorarium from ISPOR, travel expenses from Illumina, and consulting services paid to institution (UCalgary) from Novartis, outside the submitted work. The authors report no other conflicts of interest in this work."

"This study was funded by Astellas Pharma, Inc."